drugset / Trial / NCT05127174
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Phase 1
Terminated
12 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb · collab
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
Timeline
- Start
- 2022-03-14
- Primary completion
- 2025-01-03
- Completion
- 2025-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fedratinib | Small molecule | 200 mg | Oral |
| Subject | Fedratinib | Small molecule | 300 mg | Oral |
| Subject | Fedratinib | Small molecule | 400 mg | Oral |